Cannabinoid ligands targeting TRP channels by NC DOCKS at The University of North Carolina at Greensboro & Reggio, Patricia H.
Cannabinoid ligands targeting TRP channels 
 
By: Chanté Muller, Paula Morales, and Patricia H. Reggio 
 
Muller, C., Morales, P., & Reggio, P.H. (2019). Cannabinoid ligands targeting TRP channels. 
Frontiers in Molecular Neuroscience, 11, 497. https://doi.org/10.3389/fnmol.2018.00487 
 
© 2019 Muller, Morales and Reggio. Published under a Creative Commons Attribution 
International License (CC BY 4.0); https://creativecommons.org/licenses/by/4.0/. 
 
Abstract: 
 
Transient receptor potential (TRP) channels are a group of membrane proteins involved in the 
transduction of a plethora of chemical and physical stimuli. These channels modulate ion entry, 
mediating a variety of neural signaling processes implicated in the sensation of temperature, 
pressure, and pH, as well as smell, taste, vision, and pain perception. Many diseases involve TRP 
channel dysfunction, including neuropathic pain, inflammation, and respiratory disorders. In the 
pursuit of new treatments for these disorders, it was discovered that cannabinoids can modulate a 
certain subset of TRP channels. The TRP vanilloid (TRPV), TRP ankyrin (TRPA), and TRP 
melastatin (TRPM) subfamilies were all found to contain channels that can be modulated by 
several endogenous, phytogenic, and synthetic cannabinoids. To date, six TRP channels from the 
three subfamilies mentioned above have been reported to mediate cannabinoid activity: TRPV1, 
TRPV2, TRPV3, TRPV4, TRPA1, and TRPM8. The increasing data regarding cannabinoid 
interactions with these receptors has prompted some researchers to consider these TRP channels 
to be “ionotropic cannabinoid receptors.” Although CB1 and CB2 are considered to be the 
canonical cannabinoid receptors, there is significant overlap between cannabinoids and ligands 
of TRP receptors. The first endogenous agonist of TRPV1 to be discovered was the 
endocannabinoid, anandamide (AEA). Similarly, N-arachidonyl dopamine (NADA) and AEA 
were the first endogenous TRPM8 antagonists discovered. Additionally, Δ9-tetrahydrocannabinol 
(Δ9-THC), the most abundant psychotropic compound in cannabis, acts most potently at TRPV2, 
moderately modulates TRPV3, TRPV4, TRPA1, and TRPM8, though Δ9-THC is not reported to 
modulate TRPV1. Moreover, TRP receptors may modulate effects of synthetic cannabinoids 
used in research. One common research tool is WIN55,212-2, a CB1 agonist that also exerts 
analgesic effects by desensitizing TRPA1 and TRPV1. In this review article, we aim to provide 
an overview and classification of the cannabinoid ligands that have been reported to modulate 
TRP channels and their therapeutic potential. 
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Transient receptor potential (TRP) channels are a group of membrane proteins involved
in the transduction of a plethora of chemical and physical stimuli. These channels
modulate ion entry, mediating a variety of neural signaling processes implicated in
the sensation of temperature, pressure, and pH, as well as smell, taste, vision, and
pain perception. Many diseases involve TRP channel dysfunction, including neuropathic
pain, inflammation, and respiratory disorders. In the pursuit of new treatments for
these disorders, it was discovered that cannabinoids can modulate a certain subset
of TRP channels. The TRP vanilloid (TRPV), TRP ankyrin (TRPA), and TRP melastatin
(TRPM) subfamilies were all found to contain channels that can be modulated by several
endogenous, phytogenic, and synthetic cannabinoids. To date, six TRP channels from
the three subfamilies mentioned above have been reported to mediate cannabinoid
activity: TRPV1, TRPV2, TRPV3, TRPV4, TRPA1, and TRPM8. The increasing data
regarding cannabinoid interactions with these receptors has prompted some researchers
to consider these TRP channels to be “ionotropic cannabinoid receptors.” Although
CB1 and CB2 are considered to be the canonical cannabinoid receptors, there is
significant overlap between cannabinoids and ligands of TRP receptors. The first
endogenous agonist of TRPV1 to be discovered was the endocannabinoid, anandamide
(AEA). Similarly, N-arachidonyl dopamine (NADA) and AEA were the first endogenous
TRPM8 antagonists discovered. Additionally, ∆9-tetrahydrocannabinol (∆9-THC), the
most abundant psychotropic compound in cannabis, acts most potently at TRPV2,
moderately modulates TRPV3, TRPV4, TRPA1, and TRPM8, though ∆9-THC is not
reported to modulate TRPV1. Moreover, TRP receptors may modulate effects of
synthetic cannabinoids used in research. One common research tool is WIN55,212-2, a
CB1 agonist that also exerts analgesic effects by desensitizing TRPA1 and TRPV1. In this
review article, we aim to provide an overview and classification of the cannabinoid ligands
that have been reported to modulate TRP channels and their therapeutic potential.
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INTRODUCTION
Transient receptor potential (TRP) channels are a superfamily of trans-membrane ion channels
involved in transduction in response to a plethora of chemical and physical stimuli. Comprised
of four subunits with 6 trans-membrane helices (S1–S6) each, TRP channels can homo- or
heterotetramerize to create a pore for cation permeation that is located between helices 5 and
6 (Caterina, 2014). These channels are found in the plasma membrane and can gate several
types of mono- and divalent cations, in single-file fashion, through the pore following exposure
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to a stimulus. TRP channels have also been implicated as sensors
of many physiological and pathological processes including
itch, temperature sensation, cancers, genetic disorders, and pain
(Perálvarez-Marín et al., 2012; Vay et al., 2012; Caterina, 2014).
Cannabis Sativa has been used for centuries to treat
ailments including chronic pain, and extensive literature
precedent supports the role of phytogenic and endogenous
cannabinoids as pain modulators (Caterina, 2014). Chronic
pain is a significant and complex problem that encompasses
many different conditions, symptoms, and pathways. Once
nociceptors are stimulated, action potentials are generated and
then propagated to the brain, resulting in a sensation of
pain (Vay et al., 2012). Currently, the most efficient way to
treat chronic pain is with opioids, however the opioid system
also influences the reward center and long-term opioid usage
can lead to addictive behavior (Storozhuk and Zholos, 2018).
Since the etiologies related to pain and the mechanisms of
action underlying hypersensitivity are diverse, targeting the
ion channels that contribute to the detection of stimuli may
be an effective approach in treating pain syndromes (Levine
and Alessandri-Haber, 2007). Since the cloning of TRPV1,
at least five other TRP channels have been discovered in
the dorsal root ganglia (DRG), that can also be found in
primary somatosensory neurons. These channels have been
identified as sensory transducers that may participate in the
generation of painful sensations evoked by thermal, mechanical,
or chemical stimuli making them a desirable target in the
development of treatments for chronic pain syndromes (Levine
and Alessandri-Haber, 2007). One feature sought for exploitation
from these TRP channels, especially TRPV1, is desensitization.
TRPV1 becomes rapidly desensitized upon activation, rendering
the channel refractory to further stimulation. This mechanism
is thought to underlie the paradoxical analgesic effect of
TRPV1 and may explain the reduced neuronal activity upon
activation of other TRP channels (Iannotti et al., 2014). This
paradoxical analgesic effect is the basis of capsaicin-based creams
for chronic pain (De Petrocellis et al., 2011a). However, the
pungency of compounds like capsaicin can cause vascular
and respiratory side effects when administered systemically
(Luongo et al., 2012). For this reason, the use of non-pungent
compounds to activate and therefore desensitize TRP channels is
desired.
Targeting the endocannabinoid system has been shown to be a
promising strategy for the modulation of pain (Woodhams et al.,
2017). In fact, activation of the cannabinoid receptors CB1 and
CB2, as well as inhibition of endocannabinoid deactivation
(blockade of endocannabinoid uptake or degradation) has
shown antinociceptive responses (Guindon and Hohmann,
2009). Pharmacological evidence suggests that cannabinoids and
endocannabinoids target more than the canonical cannabinoid
receptors (Morales and Reggio, 2017; Morales et al., 2017, 2018).
There is evidence suggesting that some TRP channels (TRPV1–4,
TRPA1, and TRPM8) can be modulated by cannabinoids,
providing a promising multitarget approach for the treatment
of pain. Interestingly, CB1 has been suggested to colocalize with
TRP channels such as TRPV1 in sensory and brain neurons
(Ahluwalia et al., 2003; Price et al., 2004; Cristino et al., 2006),
while CB2 colocalizes with this channel in sensory neurons
and osteoclasts (Anand et al., 2008; Rossi et al., 2009). This
expression pattern makes concerted actions possible to modulate
nociceptive responses, as well as a synergistic functional effect of
cannabinoid ligands.
The mammalian TRP superfamily consists of six subfamilies:
canonical (TRPC), vanilloid (TRPV), polycystin (TRPP),
mucolipin (TRPML), ankyrin (TRPA), and melastatin (TRPM;
Winter et al., 2013). There are 28 channels in the TRP
superfamily. Six of these channels can be activated by a variety
of endogenous, phytogenic, and synthetic cannabinoids, as well
as, other physical and chemical stimuli. These six channels,
TRPV1-TRPV4, TRPA1, and TRPM8, are termed the ionotropic
cannabinoid receptors and are the focus of this review.
All TRP channels have a similar topological profile: six
transmembrane helices, a short pore helix, and a pore loop.
However, there are some structural divergences that characterize
each class of TRP channels. The main difference among the three
subfamilies discussed here is the variability in the number of
ankyrin repeat domains (ARDs) located at the N-terminus of
the receptor. Vanilloid-type channels bear a variable number of
ankyrin repeats; the Ankyrin subfamily presents a high number
of repeats; and, the TRPM subfamily lacks ankyrin repeats.
The topology of the channels reviewed here is depicted in
Figure 1. For instance, on the N-terminal side of TRPV1 lies
a series of ankyrin repeat units that form the ARD (Figure 2).
Each unit contains two short anti-parallel alpha helices and a
finger loop that extends out at a 90◦ angle from the axis of
the helices (Hellmich and Gaudet, 2014). TRPV1 specifically
contains six of these repeat units on each monomer that forms
a concave surface used for interactions with other proteins
like calmodulin (CaM) and phosphatidylinositol-3-kinase (PI3K;
Nilius and Szallasi, 2014). Similarly, TRPA1 also contains an
ARD and this class of ion channels was named for the unusually
large number of ankyrin repeats it contains (Figure 3). One
motif found in TRPA1 and TRPM8 that is not present in
the vanilloid subfamily is a C-terminal tetrameric coiled-coil
(Figures 3A,B) which mediates interactions between subunits
and is important for trafficking and function (Paulsen et al.,
2015; Yin et al., 2018). Another large structural difference
between the TRPV, TRPA, and TRPM subfamilies is the TRP
box. The TRP box is a long helix that is parallel to the
membrane, on the C-terminal side of the receptor, and can
be found in both TRPV1 and TRPM8 (Figure 2). Though
not canonically present in TRPA1 due to its location farther
below the inner leaflet (Figure 3A), the α-helix that extends
off of the C-terminal side of the receptor is topologically
and structurally analogous to a TRP box (Hellmich and
Gaudet, 2014; Paulsen et al., 2015). Despite the topological
differences among TRPV1-V4, TRPA1, and TRPM8, all respond
to select cannabinoids and are therefore classified as ionotropic
cannabinoid receptors.
Many endogenous and exogeneous compounds activate
receptors found in the TRP superfamily. Natural, pungent
compounds like capsaicin and allicin, from chili peppers
and garlic respectively, can activate and gate specific TRP
channels. In addition to these pungent compounds, the six
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FIGURE 1 | General topology of the transient receptor potential (TRP)
channels discussed in this review: TRPV1–4, TRPA1 and TRPM8.
TRP channels that make up the ionotropic cannabinoid
receptors can also be modulated by endogenous, phytogenic,
and synthetic cannabinoids. For example, the endocannabinoid
anandamide (AEA, Figure 4) was the first endogenous
TRPV1 agonist identified during a study of the vasodilator
action of AEA (Zygmunt et al., 1999). N-arachidonyl dopamine
(NADA, Figure 4) and AEA were identified as the first
endogenous antagonists of TRPM8 (De Petrocellis et al.,
2007). ∆9-tetrahydrocannabinol (∆9-THC, Figure 5) acts most
potently at TRPV2; moderately modulates TRPV3, TRPV4,
TRPA1, and TRPM8; but, does not appear to modulate TRPV1
(De Petrocellis et al., 2011b). Cannabidiol (CBD, Figure 5)
has been shown to have many beneficial properties, including
anti-inflammatory action. CBD has little affinity for the CB1 and
CB2 receptors, but is reported to be most potent at TRPV1 and
TRPM8 channels (De Petrocellis et al., 2011b). A common
synthetic cannabinoid known for its use as a CB1 agonist,
WIN55,212-2 (Figure 6), has been found to exert analgesic
effects by desensitizing both TRPV1 and TRPA1 (Ruparel et al.,
2011).
FIGURE 2 | The lipid view of TRPV1 adapted from PDB: 3J5P. Ankyrin repeat
domain (ARD) shown in red, transmembrane helices shown in yellow, TRP
domain shown in purple, and intracellular regions (ICRs) and extracellular
regions (ECRs) shown in green. Sections have been omitted for clarity.
There are many more cannabinoid ligands that target the
ionotropic cannabinoid receptors. In this review, we provide an
overview and classification of the various cannabinoid ligands
that modulate the ionotropic cannabinoid receptors and we
explore the therapeutic potential of these ligands.
TRPV1
TRPV1, also known as the capsaicin receptor, is a polymodal,
nonselective cation channel expressed by all major classes of
nociceptive neurons and is important for the detection of
noxious stimuli (Vay et al., 2012; Caterina, 2014). Ion channels,
including TRPV1, are typically found in the plasma membrane
and form a passageway from one side of the membrane to the
other (De Petrocellis et al., 2017). Upon activation, the pore
of TRPV1 opens and allows ions to pass from one side of the
membrane to the other. TRPV1 can be activated by a number
of endogenous and exogenous stimuli including heat, N-acyl
amides, arachidonic acid (AA) derivatives, vanilloids, protons
and cannabinoids (De Petrocellis et al., 2017).
Two agonists, capsaicin and resiniferatoxin (RTX), potently
activate TRPV1 and evoke strong burning sensations. Upon
activation, calcium preferentially moves through the pore, enters
the cell and stimulates a series of calcium-dependent processes
that ultimately lead to desensitization of the channel. Upon
desensitization, the channel enters a refractory period in which
it can no longer respond to further stimulation, leading to the
paradoxical analgesic effect of these compounds (Iannotti et al.,
2014). However, capsaicin and RTX can cause ablation of the
nociceptive terminals. This, in turn, can cause a loss of the
ability to identify potential tissue-damaging stimuli in the future
(Chung and Campbell, 2016). Due to this, different avenues have
been, and are currently, being explored to find ways to desensitize
the channel without painful or ablative effects.
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FIGURE 3 | (A) The lipid view of TRPA1 adapted from PDB: 3J9P. ARD shown in red, transmembrane region (TMR) shown in yellow, TRP-like domain shown in
purple, ICRs- and ECRs shown in green and coiled-coil shown in pink. Sections have been omitted for clarity. (B) The intracellular view of TRPA1 adapted from PDB:
3J9P. Coiled-coil shown in pink. Sections have been omitted for clarity.
FIGURE 4 | Structure of selected endocannabinoids that target TRP channels.
One avenue that has been explored is the modulation
of TRP channels by cannabinoids. Endocannabinoids are the
endogenous ligands that activate the CB1 and CB2 receptors,
but they also activate the ionotropic cannabinoid receptors.
AEA (Figure 4), an N-acyl amide, was the first endogenous
agonist identified to activate TRPV1 (Zygmunt et al., 1999).
AEA has a similar binding affinity as capsaicin, although
capsaicin is significantly more potent (Storozhuk and Zholos,
2018). Palmitoylethanolamide (PEA, Figure 4), a congener
of AEA, has low affinity for both CB1 and CB2 receptors,
but activates TRPV1, albeit at very high concentrations
(Petrosino et al., 2016). However, Petrosino and colleagues
have shown that PEA enhances the effects of AEA at both the
cannabinoid receptors and TRPV1 by inhibiting the degradation
of AEA (De Petrocellis and Di Marzo, 2005; Petrosino et al.,
2016).
Other N-acyl amides have also shown activity at TRPV1.
AEA analogs, such as NADA and N-oleoyl DA (OLDA),
are structurally similar to both capsaicin and AEA and
have been shown to activate TRPV1 and TRPV4 receptors
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FIGURE 5 | Structure of selected plant cannabinoid ligands that target TRP channels.
(Huang et al., 2002; Raboune et al., 2014). N-acyl GABA
(NGABA), N-acyl aspartic acid (NAsp), N-acyl glycine (NGly),
and N-acyl serine (NSer) also have significant agonist activity at
TRPV1 (Raboune et al., 2014).
In addition to capsaicin and RTX, many other stimuli
including heat, protons, and phytocannabinoids can activate
TRPV1 (Millan, 1999; Vandewauw et al., 2018). As reported
by Bisogno and colleagues in 2001, CBD was shown to act
as an agonist of TRPV1 in HEK—TRPV1 cells without the
ablative effects of capsaicin and RTX (Bisogno et al., 2001; De
Petrocellis et al., 2011b). Another study performed by Ligresti
et al. (2006) suggests that CBD can induce apoptosis in breast
carcinoma cells through either direct or indirect activation of
CB2 and/or TRPV1. CBD and its phytocannabinoid analog
cannabidivarin (CBDV, Figure 5) have been shown to act as
negative allosteric modulators of CB1 (Laprairie et al., 2015) or
in a CB1-independent manner, respectively (Hill et al., 2013).
CBD has been reported to activate TRPV1 at low micromolar
concentrations similar to CBDV, and although CBDV is a weaker
TRPV1 agonist than capsaicin, it still retains a high potency
at TRPV1 (Iannotti et al., 2014). In line with these findings,
CBD has been proven to exert anti-hyperalgesic benefits that
may result from underlying activation and desensitization of
TRPV1 at the peripheral and spinal level. This suggests that
CBD may have therapeutic potential against inflammatory and
chronic pain (De Petrocellis et al., 2011b). While many other
phytocannabinoids show very weak and often barely measurable
efficacies, CBD and cannabigerol (CBG, Figure 5) have been
shown to be the most potent at TRPV1 and TRPM8 (De
Petrocellis et al., 2011b). Furthermore, in a study of the effects
of cannabinoids and cannabinoid-enriched Cannabis extracts
on ionotropic TRP channels, De Petrocellis et al. (2011b)
found that ∆9-tetrahydrocannabivarin (THCV, Figure 5) and
cannabigevarin (CBGV, Figure 5) also stimulated TRPV1, while
their acid analogs (CBDA, CBGA) stimulated TRPV1 to a lesser
extent. ∆9-THC and its acid metabolite, ∆9-THCA, were not
found to modulate the channel. Likewise, cannabichromene
(CBC, Figure 5) and cannabinol (CBN, Figure 5) were shown
to have very low efficacies at TRPV1 (De Petrocellis et al.,
2011b).
Synthetic cannabinoids can also modulate TRPV1. For
instance, in a collaborative effort between academia and the
pharmaceutical industry, Soethoudt et al. (2017) studied the
pharmacology of diverse CB2 ligands. In this work, 11 synthetic
cannabinoids were tested on the ionotropic cannabinoid
receptors. Putative factors in synthetic cannabinoid ligand
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FIGURE 6 | Structure of selected synthetic cannabinoid ligands that target TRP channels: (A) aminoalkyindole derivatives; (B) arylpyrazole derivatives; (C) synthetic
phytocannabinoids analogs.
binding at TRPV1 seem to be different among classes of synthetic
cannabinoids. While binding modes for these ligands remain
unknown currently some structural features can be elucidated
from the scarce SAR reported. The phytocannabinoid synthetic
analogs HU308, HU910, and JWH133 (Figure 6), which
activate CB2 receptors, were found to weakly modulate TRPV1.
Aminoalkylindole and arylpyrazole derivatives, well-known
cannabinoid synthetic scaffolds, were also evaluated at these
channels (Soethoudt et al., 2017). Among the aminoalkylindoles
tested, the CB1/CB2 ligand WIN55,212-2 (Figure 6), was
found to be the most efficacious TRPV1 ligand (Soethoudt
et al., 2017). Both enantiomers of the aminoalkylindole
AM1241 (S and R, Figure 6) had low efficacies at TRPV1,
whereas AM630 did not appear to modulate TRPV1 at
measurable values. This may indicate that the dihydro-oxazine
indole core of WIN55,212-2 might be crucial for optimized
TRPV1 activity, while bulky aminoalkylindole substituents and
electron withdrawing phenyl substituents may also play a role
in this channel. Moreover, arylpyrazoles SR141716A, SR144528,
AM251, and Gp-1a (Figure 6) were also assessed at these
channels. SR141716A was found to be a partial agonist of
TRPV1, while Gp-1a was able to desensitize TRPV1 in the low
micromolar range (De Petrocellis et al., 2001; Soethoudt et al.,
2017). SR144528 and AM251 failed to modulate this channel.
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These results prompt us to speculate that the role of the chlorine
in the chlorophenyl moiety of SR141716A, which is an iodine in
AM251, is essential, the latter halogen being too bulky.Moreover,
the rigidity conferred to the molecule by the tricycle in Gp-1a
also decreases activity, while the bulkier pyrazole substituents
of SR144528 totally abolished activity at this channel. Further
studies need to be done to see how these structural changes affect
the binding mode within the TRPV1 pocket.
Table 1 below summarizes all these data on endo-, phyto-, and
synthetic cannabinoids that have been tested at TRPV1, along
with their potencies, efficacies, and desensitization values.
TRPV2
The second member of the vanilloid subfamily, TRPV2, shares
50% sequence identity with TRPV1. TRPV2 is widely expressed
in a subpopulation of medium and large diameter sensory
neurons (Vay et al., 2012; Caterina, 2014). TRPV2 is insensitive to
protons and capsaicin, but can be activated by high temperatures
and inflammation (De Petrocellis et al., 2017). Similar to TRPV1,
the activation and desensitization of TRPV2 is deeply involved
in inflammatory and chronic pain (Levine and Alessandri-
Haber, 2007). Therefore, finding cannabinoid ligands that can
activate and subsequently desensitize TRPV2 may be a desirable
therapeutic strategy.
While TRPV1 is activated by endogenous, phytogenic,
and synthetic cannabinoids, TRPV2 is mainly activated by
phytocannabinoids (De Petrocellis et al., 2017; Soethoudt et al.,
2017). Two N-acyl amides, N-acyl proline (NPro) and N-acyl
tyrosine (NTyr), are the onlyN-acyl amides that have been shown
to activate TRPV2 with any significance (Raboune et al., 2014).
Endogenous ligands such as AEA, 2-arachidonoylglycerol (2-AG,
Figure 4), and NADA barely elicit a response from TRPV2 (Qin
et al., 2008).
CBD has been found to be the most potent and efficacious
phytocannabinoid that activates TRPV2, although at slightly
lower values than at TRPV1 (Qin et al., 2008; De Petrocellis
et al., 2011b). CBC (Figure 5) and the carboxylic acid derivatives
CBGA and CBDA (Figure 5) are inactive at TRPV2, while
the acid metabolite of ∆9-THC, ∆9 -THCA (Figure 5), has
a weaker potency (De Petrocellis et al., 2011b). ∆9-THC has
been identified as the most potent phytocannabinoid at TRPV2,
although it is not selective, as it also activates TRPA1 (Qin et al.,
2008). Conversely, an analog of ∆9-THC, 11-OH-∆9-THC was
found to have a low response at TRPV2, suggesting the hydroxy
group somehow disrupts the activation and/or binding mode of
∆9-THC. However, THCV, containing a shortened alkyl side
chain (propyl vs. pentyl), and ∆9-THCA, both act as agonists
at TRPV2 with the best desensitizing ligand being THCV (De
Petrocellis et al., 2011b). This suggests that the THC scaffold is
robust enough to withstand moderate changes and still maintain
activity at TRPV2. Further structure-activity relationships on this
chemotype may allow fine-tuning of phytocannabinoid activity
at this channel.
Wanting to expand on the identity of cannabinoids that
activate TRPV2, Qin et al. (2008) tested a variety of synthetic
cannabinoids including the THCmimics, nabilone and CP55940
(Figure 6, Table 2). Both had comparable response rates at
58% and 42%, respectively, and were the most responsive of the
synthetic cannabinoids tested. The synthetic phytocannabinoid
analog JWH133 (Figure 6), a potent and selective CB2 agonist,
was also determined to have a very low response rate at
rat TRPV2 (Qin et al., 2008). The more commonly used
aminoalkylindole derivative, WIN55,212-2, was shown to have
no, or very weak, response in rat TRPV2, but maintained a
relatively high response rate in rat TRPA1 (Qin et al., 2008).
In summary, the data reported thus far (see Table 2) indicates
that ∆9-THC, its mimics, and derivatives, have the best efficacies
at TRPV2, with the exception of 11-OH-∆9-THC. These results
could be further expanded upon and utilized to develop new and
highly selective TRPV2 agonists.
TRPV3
The third member of the vanilloid subfamily, TRPV3, shares
a 43% sequence homology with TRPV1 and is predominantly
expressed in the DRG, trigeminal ganglia, and in the brain,
as well as, several peripheral tissues such as testis, skin
and tongue (De Petrocellis et al., 2017). The role of this
channel is directly related to the perception of pain and
itch. TRPV3 also acts as a thermosensor of innocuous warm
temperatures (33–39◦C; Pedersen et al., 2005). In addition
to being activated by innocuous warm temperatures, the
cooling-agent camphor and carvacrol, found in the oil of
oregano and thyme, can also activate this channel (Caterina,
2014).
In contrast to TRPV1, only a few studies have demonstrated
the activity of cannabinoids in this thermosensitive channel.
So far, no canonical endocannabinoid has been reported to
target TRPV3. However, in a recent study using endogenous
lipids structurally related to AEA, N-acyl valine (NVal)
mixtures were shown to exhibit antagonistic activity at
this channel (Raboune et al., 2014). In particular, N-
docosahexaenoyl, N-linoleoyl, N-oleoyl, and N-stearoyl
valine were identified as individual hit antagonists, whereas
no agonist was discovered among the lipids tested (Raboune
et al., 2014).
When De Petrocellis et al. (2012a) tested
12 phytocannabinoids against TRPV3, they found that 10 of
them exerted significant elevation of intracellular calcium, but
that CBD and THCV were able to modulate TRPV3 with an
efficacy similar to that of its typical agonist, carvacrol (Table 3).
The authors reported that while these two phytocannabinoids
potently activate TRPV3, cannabigerovarin (CBGV) and CBG
acid (CBGA) were significantly more efficacious at desensitizing
this channel to subsequent carvacrol activation, suggesting that
the CBG scaffold may serve as a structural basis to develop
TRPV3 desensitizers (De Petrocellis et al., 2012a).
Synthetic cannabinoids have only recently been tested
at TRPV3 (Soethoudt et al., 2017). The 1,1-dimethylheptyl
phytocannabinoid derivative HU-910 was shown to activate
TRPV3 with submicromolar potency. Interestingly, this
compound does not modulate any other TRP channel tested.
Other compounds such as the arylpyrazoles SR141716A and
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TABLE 2 | Functionality of phytogenic, endogenous, and synthetic cannabinoid ligands at TRPV2.
TRPV2
Compound Functionality Efficacy∗ (µM) Potency EC50 (µM) Desensitization∗∗ (µM) Cell type References
AEA Agonist NA - - TRPV2-HEK-293 Qin et al. (2008)
2-AG Agonist 29 - - TRPV2-HEK-293 Qin et al. (2008)
NPro Agonist 73.35 ± 2.20 - - TRPV2-HEK-293 Raboune et al. (2014)
NTyr Agonist 74.78 ± 15.21 - - TRPV2-HEK-293 Raboune et al. (2014)
CBD Agonist 40.5 ± 1.6 1.25 ± 0.23 4.5 ± 0.7 TRPV2-HEK-293 De Petrocellis et al. (2011b)
CBDA - <10 ND 114.0 ± 18.0 TRPV2-HEK-293 De Petrocellis et al. (2011b)
CBDV Agonist 49.9 ± 0.9 7.3 ± 0.4 31.1 ± 0.2 TRPV2-HEK-293 De Petrocellis et al. (2011b)
CBG Agonist 73.6 ± 1.2 1.72 ± 0.08 1.5 ± 0.2 TRPV2-HEK-293 De Petrocellis et al. (2011b)
CBGA - <10 ND 87.3 ± 1.2 TRPV2-HEK-293 De Petrocellis et al. (2011b)
CBGV Agonist 75.4 ± 2.4 1.41 ± 0.36 0.7 ± 0.06 TRPV2-HEK-293 De Petrocellis et al. (2011b)
CBC - <10 ND 6.5 ± 1.6 TRPV2-HEK-293 De Petrocellis et al. (2011b)
CBN Agonist 39.9 ± 2.1 19.0 ± 3.7 15.7 ± 2.1 TRPV2-HEK-293 De Petrocellis et al. (2011b)
THC Agonist 53.0 ± 1.4 0.65 ± 0.05 0.8 ± 0.1 TRPV2-HEK-293 De Petrocellis et al. (2011b)
98 15.5 - TRPV2-HEK-293 Qin et al. (2008)
11-OH-THC - 57 - - TRPV2-HEK-293 Qin et al. (2008)
THCV Agonist 73.8 ± 1.0 4.11 ± 0.11 0.8 ± 0.5 TRPV2-HEK-293 De Petrocellis et al. (2011b)
THCA Agonist 68.2 ± 1.0 18.4 ± 0.9 9.8 ± 2.6 TRPV2-HEK-293 De Petrocellis et al. (2011b)
SR141716A - <10 NA >100 TRPV2-HEK-293 Soethoudt et al. (2017)
SR144528 - <10 NA >50 TRPV2-HEK-293 Soethoudt et al. (2017)
AM251 - <10 NA 18.4 ± 3.5 TRPV2-HEK-293 Soethoudt et al. (2017)
Gp-1a - <10 NA 11.9 ± 0.7 TRPV2-HEK-293 Soethoudt et al. (2017)
WIN55,212-2 - NA - - TRPV2-HEK-293 Qin et al. (2008)
(R)-AM1241 Agonist 14.5 ± 0.3 12.0 ± 3.1 35.5 ± 1.5 TRPV2-HEK-293 Soethoudt et al. (2017)
(S)-AM1241 Agonist 11.6 ± 0.1 5.0 ± 0.1 20.6 ± 3.1 TRPV2-HEK-293 Soethoudt et al. (2017)
AM630 - <10 NA 35.6 ± 1.4 TRPV2-HEK-293 Soethoudt et al. (2017)
HU308 - <10 NA >100 TRPV2-HEK-293 Soethoudt et al. (2017)
HU910 - <10 NA >100 TRPV2-HEK-293 Soethoudt et al. (2017)
JWH133 - 4 - - TRPV2-HEK-293 Qin et al. (2008)
CP55940 Agonist 42 - - TRPV2-HEK-293 Qin et al. (2008)
Nabilone Agonist 58 - - TRPV2-HEK-293 Qin et al. (2008)
∗Efficacy as % of ionomycin 4 µM. ∗∗Desensitization vs. standardized agonist (3 µM lysophosphatidylcholine) at IC50 concentrations. NA, No activity; ND, Not determined.
AM251 showed agonist activity at TRPV3, however, they are not
selective since they also exhibited activity at other TRP channels.
Since studies of TRPV3 and its interactions with cannabinoids
are limited, further investigation is required to aid in the
elucidation of key structural features within each cannabinoid
ligand subclass. These discoveries could be used to develop new
synthetic cannabinoids that lead to more potent compounds
that act at this channel. However, unlike TRPV1, TRPV3 has
been shown to exhibit sensitization in response to repetitive
heat stimuli (Chung et al., 2004). Due to this, studies
should be performed to determine if ligand activation of
TRPV3 causes a similar sensitization effect as heat activation,
in which case, antagonists would be better suited for this
channel.
TABLE 3 | Functionality of phytogenic, endogenous, and synthetic cannabinoid ligands at TRPV3.
TRPV3
Compound Functionality Efficacy∗ (µM) Potency EC50 (µM) Desensitization∗∗ (µM) Cell type References
NVal Antagonist - - 39.73 ± 4.16 TRPV3-HEK-293 Raboune et al. (2014)
CBD Agonist 50.1 ± 4.8 3.7 ± 1.6 0.9 ± 0.3 TRPV3-HEK-293 De Petrocellis et al. (2012a)
THCV Agonist 72.4 ± 2.4 3.8 ± 0.4 3.0 ± 0.2 TRPV3-HEK-293 De Petrocellis et al. (2012a)
CBGA Agonist 17.5 ± 1.3 12.6 ± 0.2 7.4 ± 1.2 TRPV3-HEK-293 De Petrocellis et al. (2012a)
CBGV Agonist 23.5 ± 1.7 2.4 ± 0.8 0.8 ± 0.04 TRPV3-HEK-293 De Petrocellis et al. (2012a)
SR141716A Agonist 38.9 ± 2.1 0.85 ± 0.15 3.4 ± 0.4 TRPV3-HEK-293 Soethoudt et al. (2017)
SR144528 - <10 NA >100 TRPV3-HEK-293 Soethoudt et al. (2017)
AM251 Agonist 25.9 ± 1.3 0.6 ± 0.1 >50 TRPV3-HEK-293 Soethoudt et al. (2017)
Gp-1a - <10 NA 22.6 ± 3.9 TRPV3-HEK-293 Soethoudt et al. (2017)
WIN55,212-2 Agonist 22.9 ± 0.6 6.5 ± 0.9 >100 TRPV3-HEK-293 Soethoudt et al. (2017)
(R)-AM1241 Agonist 12.9 ± 0.1 10.0 ± 0.1 >50 TRPV3-HEK-293 Soethoudt et al. (2017)
(S)-AM1241 Agonist 16.2 ± 0.1 9.0 ± 0.1 >50 TRPV3-HEK-293 Soethoudt et al. (2017)
AM630 - <10 NA >100 TRPV3-HEK-293 Soethoudt et al. (2017)
HU308 - <10 NA >100 TRPV3-HEK-293 Soethoudt et al. (2017)
HU910 Agonist 31.3 ± 2.2 0.12 ± 0.05 12.9 ± 4.2 TRPV3-HEK-293 Soethoudt et al. (2017)
JWH133 - <10 NA 80.6 ± 1.4 TRPV3-HEK-293 Soethoudt et al. (2017)
∗Efficacy as % of ionomycin 4 µM. ∗∗Desensitization vs. standardized agonist (carvacrol) at EC50 concentrations or IC50 for antagonism. NA, No activity.
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TABLE 4 | Functionality of phytogenic, endogenous, and synthetic cannabinoid ligands at TRPV4.
TRPV4
Compound Functionality Efficacy∗ (µM) Potency EC50 (µM) Desensitization∗∗ (µM) Cell type References
AEA Agonist (Indirect activation) - - - TRPV4-HEK-293 Watanabe et al. (2003)
2-AG Agonist (Indirect activation) - - - TRPV4-HEK-293 Watanabe et al. (2003)
NTyr Agonist - 55.59 ± 7.79 - TRPV4-HEK-293 Raboune et al. (2014)
NTrp Agonist - 75.59 ± 7.79 - TRPV4-HEK-293 Raboune et al. (2014)
CBDV Agonist 30.2 ± 0.9 0.9 ± 0.1 2.9 ± 0.3 TRPV4-HEK-293 De Petrocellis et al. (2012a)
THCV Agonist 59.8 ± 1.7 6.4 ± 0.7 3.2 ± 0.2 TRPV4-HEK-293 De Petrocellis et al. (2012a)
CBG Agonist 23.7 ± 1.8 5.1 ± 1.6 1.3 ± 0.1 TRPV4-HEK-293 De Petrocellis et al. (2012a)
CBGA Agonist 36.5 ± 1.9 28.8 ± 0.3 3.6 ± 0.3 TRPV4-HEK-293 De Petrocellis et al. (2012a)
CBGV Agonist 26.1 ± 1.7 22.2 ± 3.7 1.8 ± 0.1 TRPV4-HEK-293 De Petrocellis et al. (2012a)
CBN Agonist 15.3 ± 1.5 16.1 ± 4.5 5.4 ± 0.8 TRPV4-HEK-293 De Petrocellis et al. (2012a)
SR141716A - <10 NA 2.0 ± 0.1 TRPV4-HEK-293 Soethoudt et al. (2017)
SR144528 - <10 NA >100 TRPV4-HEK-293 Soethoudt et al. (2017)
AM251 - <10 NA 1.2 ± 0.1 TRPV4-HEK-293 Soethoudt et al. (2017)
Gp-1a - <10 NA 2.2 ± 0.1 TRPV4-HEK-293 Soethoudt et al. (2017)
WIN55,212-2 - <10 NA 16.1 ± 1.7 TRPV4-HEK-293 Soethoudt et al. (2017)
(R)-AM1241 - <10 NA 8.7 ± 0.5 TRPV4-HEK-293 Soethoudt et al. (2017)
(S)-AM1241 - <10 NA 8.6 ± 0.3 TRPV4-HEK-293 Soethoudt et al. (2017)
AM630 - <10 NA 3.2 ± 0.1 TRPV4-HEK-293 Soethoudt et al. (2017)
HU308 - <10 NA >100 TRPV4-HEK-293 Soethoudt et al. (2017)
HU910 - <10 NA >100 TRPV4-HEK-293 Soethoudt et al. (2017)
JWH133 - 13.6 ± 0.8 12.0 ± 3.0 >100 TRPV4-HEK-293 Soethoudt et al. (2017)
∗Efficacy as % of ionomycin 4 µM. ∗∗Desensitization vs. standardized agonist (4-α-phorbol-12,13-didecanoate, 4αPDD) at EC50 concentrations. NA, No activity.
TRPV4
The fourth and final member of the vanilloid subfamily discussed
here shares over 40% sequence homology with TRPV1 (Nilius
et al., 2004). This receptor is widely expressed throughout the
body and can be found in the central nervous system, epithelial
cells, osteoblasts, blood vessels, and many other tissues including
those of the heart, liver, and kidney (Nilius and Owsianik,
2011). TRPV4 is involved in the regulation of systemic osmotic
pressure in the brain, and plays a role in vascular function,
TABLE 5 | Functionality of phytogenic, endogenous, and synthetic cannabinoid ligands at TRPA1.
TRPA1
Compound Functionality Efficacy∗ (µM) Potency EC50 (µM) Desensitization∗∗ (µM) Cell type References
AEA Agonist 158.7 ± 11.1 10.1 ± 1.9 21.0 ± 1.6 TRPA1-HEK-293 De Petrocellis et al. (2012b)
AA Agonist - 13 ± 4 - TRPA1-HEK-293 Redmond et al. (2014)
ACEA Agonist - 12 ± 2.0 NS TRPA1-CHO Akopian et al. (2008)
THC Agonist 117 ± 12 0.23 ± 0.03 - TRPA1-HEK-293 De Petrocellis et al. (2008)
THCA Agonist 41.6 ± 2.1 2.7 ± 0.9 95.25 ± 0.01 TRPA1-HEK-293 De Petrocellis et al. (2011b)
THCV Agonist 234.0 ± 16.5 1.5 ± 0.6 3.07 ± 0.24 TRPA1-HEK-293 De Petrocellis et al. (2011b)
THCVA Agonist 170.2 ± 15.9 16.4 ± 2.4 13.14 ± 0.85 TRPA1-HEK-293 De Petrocellis et al. (2011b)
CBD Agonist 115.9 ± 4.6 0.11 ± 0.05 0.16 ± 0.05 TRPA1-HEK-293 De Petrocellis et al. (2011b)
CBDA Agonist 113.0 ± 11 5.3 ± 1.5 4.92 ± 0.09 TRPA1-HEK-293 De Petrocellis et al. (2011b)
CBDV Agonist 105.0 ± 0.7 0.42 ± 0.01 1.29 ± 0.38 TRPA1-HEK-293 De Petrocellis et al. (2011b)
CBC Agonist 119.4 ± 3.1 0.09 ± 0.01 0.37 ± 0.05 TRPA1-HEK-293 De Petrocellis et al. (2011b)
CBG Agonist 99.9 ± 1.1 0.7 ± 0.03 13.0 ± 4.8 TRPA1-HEK-293 De Petrocellis et al. (2011b)
CBGA Agonist 182.8 ± 0.2 8.4 ± 3.5 7.14 ± 0.17 TRPA1-HEK-293 De Petrocellis et al. (2011b)
CBGV Agonist 151.4 ± 0.9 1.6 ± 0.01 2.02 ± 0.25 TRPA1-HEK-293 De Petrocellis et al. (2011b)
CBN Agonist 83.3 ± 4.0 0.18 ± 0.02 0.40 ± 0.04 TRPA1-HEK-293 De Petrocellis et al. (2011b)
SR141716A Agonist 67.3 ± 1.2 1.9 ± 0.1 12.5 ± 2.2 TRPA1-HEK-293 Soethoudt et al. (2017)
SR144528 Agonist 43.8 ± 1.4 8.9 ± 1.2 >100 TRPA1-HEK-293 Soethoudt et al. (2017)
AM251 Agonist 44.4 ± 0.7 0.86 ± 0.06 17.1 ± 2.2 TRPA1-HEK-293 Soethoudt et al. (2017)
Gp-1a Agonist 83.6 ± 0.9 2.1 ± 0.1 10.4 ± 1.4 TRPA1-HEK-293 Soethoudt et al. (2017)
WIN55,212-2 Agonist 72.3 ± 0.9 2.3 ± 0.1 6.4 ± 0.6 TRPA1-HEK-293 Soethoudt et al. (2017)
(R)-AM1241 Agonist 19.8 ± 1.3 19.5 ± 5.8 >50 TRPA1-HEK-293 Soethoudt et al. (2017)
(S)-AM1241 Agonist 47.5 ± 0.8 5.8 ± 0.4 40.9 ± 5.9 TRPA1-HEK-293 Soethoudt et al. (2017)
AM630 Agonist 118.0 ± 2.0 1.9 ± 0.2 3.7 ± 0.5 TRPA1-HEK-293 Soethoudt et al. (2017)
HU910 Agonist 33.1 ± 0.1 53.1 ± 1.1 >100 TRPA1-HEK-293 Soethoudt et al. (2017)
HU308 Agonist 43.1 ± 2.2 18.5 ± 3.9 >100 TRPA1-HEK-293 Soethoudt et al. (2017)
JWH133 Agonist 76.8 ± 3.8 8.5 ± 2.3 20.0 ± 3.2 TRPA1-HEK-293 Soethoudt et al. (2017)
∗Efficacy as % of 100 µM allyl isothiocyanate. ∗∗Desensitization vs. standardized agonist (100 µM allyl isothiocyanate) at IC50 concentrations. NS, Not Significant.
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skin barrier function and nociception (Strotmann et al., 2000;
Liedtke, 2005; Nilius and Owsianik, 2011). Similar to TRPV3,
this channel responds to warm thermal changes, being activated
by temperatures from 25◦C to 34◦C. In addition to diverse
exogenous and endogenous ligands, TRPV4 is also activated by
mechanical and osmotic stimuli (Vincent and Duncton, 2011;
Duncton, 2015).
In 2003, Watanabe and coworkers reported the first
experiments that linked endogenous cannabinoids to
TRPV4 modulation. The authors proposed that the most
abundant endocannabinoids, AEA and 2-AG, are able to activate
this channel. This robust activation of TRPV4 is suggested to
be due to AA metabolites formed by cytochrome P450, such
as epoxyeicosatrienoic acids (Watanabe et al., 2003). Though
further research is needed to unravel structural determinants
of ligand-receptor interactions, the epoxy group generated
upon epoxygenase metabolism of the polyunsaturated fatty
acids found in endocannabinoids may be essential for ligand
activity. Moreover, in the previously mentioned study of
endogenous lipids, certain N-acyl amides were identified as
TRPV4 modulators (Raboune et al., 2014). Among them, NTyr
and N-acyl tryptophan (NTrp) mixtures stand out because of
their agonist activity at TRPV4.
Concerning plant-derived cannabinoids, De Petrocellis et al.
(2012a) discovered that specific compounds are also able to
evoke intracellular Ca2+ response in cells expressing TRPV4. As
depicted in Table 4, phytogenic analogs of CBD and ∆9-THC
bearing a propyl side chain, CBDV and THCV, showed the
highest efficacy and potency among the phytocannabinoids
tested. These results may prompt consideration of the structural
importance of cannabinoid lipophilic side chains and their
interactions at TRPV4.
On the other hand, phytocannabinoids such as CBG,
CBGA, CBGV, and CBN (Figure 5) were more readily
able to desensitize this channel (after activation by 4-α-
phorbol-12,13-didecanoate, 4α-PDD), even though these
phytocannabinoids exhibited low efficacy and/or potency
as activators of this channel. It is interesting to highlight
that CBC reduced TRPV4 expression in the jejunum and
ileum of mice treated with a gastrointestinal inflammatory
agent, but not in control mice (De Petrocellis et al.,
2012a).
Synthetic cannabinoid derivatives from representative
structural families, such as aminoalkyindoles or arylpyrazoles
have also been tested at this channel (Soethoudt et al., 2017).
These ligands, including the CB1/CB2 agonist WIN55212-2, the
cannabinoid inverse agonists SR141716A and SR144528, and the
CB2 selective agonists HU-308 and HU-910 all failed to stimulate
TRPV4 in the reported assays (Table 4).
More cannabinoids remain to be tested at this channel to
determine the relevance of TRPV4 within the cannabinoid
system.
TRPA1
The first and only member of the ankyrin family to be discussed
in this review is TRPA1. Members of this family are named for
their extensive ARDs. TRPA1 itself contains 16 ankyrin repeat
units in comparison to the six that TRPV1 contains (Paulsen
et al., 2015). TRPA1 can be found co-expressed with TRPV1 in
a subset of peripheral sensory neurons and is activated by
pungent compounds found in mustard, garlic, and onion. These
pungent compounds, called isothiocyanates, are electrophiles
that covalently bind to cysteine or lysine residues found in the
ARD (Caterina, 2014; Paulsen et al., 2015). TRPA1 channels
have also been shown to mediate mechanical and bradykinin-
evoked hyperalgesia, playing an important role in neuropathic
and inflammatory pain (Yekkirala, 2013). In addition to these
various ligands, TRPA1 is also activated by temperatures below
17◦C, putting it at the low end of the thermo-TRP scale (Vay
et al., 2012).
Very few endocannabinoids have shown activity at TRPA1.
AEA was determined to have a very high efficacy (∼159%)
when compared to the typical TRPA1 agonist, mustard oil
isothiocyanates (MO), and AEA and AA were both found to
exhibit low micromolar potencies (De Petrocellis et al., 2012b;
Redmond et al., 2014). Currently, these are the only two
endocannabinoids with reported activity at this channel, which
leaves room to discover other endogenous ligands.
In contrast to the few endocannabinoids that act at
TRPA1, many phyto- and synthetic cannabinoids have been
reported to activate this channel. De Petrocellis et al. (2008)
tested various phytocannabinoids in TRPA1-HEK-293 cells
and found that CBC, CBD, ∆9-THCA, CBDA, and CBG all
increased intracellular Ca2+ levels. When the efficacy of CBC,
∆9-THC, and CBG was tested, it was shown that these three
phytocannabinoids are more efficacious than MO. However,
∆9-THCA and CBDA are considered to be partial agonists of
TRPA1, since they were determined to have a slightly lower
efficacy than MO (De Petrocellis et al., 2008). The most potent of
the phytocannabinoids initially tested were CBC, CBD, and CBN
with EC50 values of 90 nM, 110 nM, and 180 nM respectively
(De Petrocellis et al., 2011b). Later, De Petrocellis et al. (2011b)
tested a wider variety of phytocannabinoids and, in agreement
with their previous data, found that CBC and CBD exhibited
the highest potency. However, the acid derivatives, CBGA,
CBDA, and∆9-THCA all showed weaker activation at TRPA1 in
response to subsequent application of MO, confirming their role
as partial agonists. This data shows that while the acid derivatives
of phytocannabinoids can still agonize the channel, it is to a lesser
extent than their decarboxylated analogs.
In addition to the phytocannabinoids that have been tested,
many synthetic cannabinoids have been evaluated showing
activity at TRPA1. The synthetic endocannabinoid and CB1
agonist, arachidonyl-2’-chloroethylamine (ACEA), was shown to
have a potency similar to that of AEA at TRPA1 (Akopian et al.,
2008; Ruparel et al., 2011), while the arylpyrazoles SR141716A,
Gp-1a, and AM251, and the aminoalkyindoles WIN55,212-2
and AM630 were determined to activate this channel more
potently than ACEA (Soethoudt et al., 2017). Furthermore,
HU308, HU910, (R)-AM1241, and SR144528 all displayed low
or no desensitization ability and slightly lower potencies than
the previously mentioned synthetic cannabinoids. However,
the phytocannabinoid analog JWH133 was found to be one
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of the most efficacious synthetic cannabinoids tested at this
channel with an efficacy of ∼76%. These data suggest that a
wide-spanning variety of synthetic cannabinoids can activate
TRPA1 with low micromolar potencies. Table 5 summarizes
functional data for synthetic cannabinoids tested.
TRPA1 is suggested to play a role in many different disease
states and may be involved in the mediation of the therapeutic
effects of cannabinoids (Romano et al., 2013; Araújo et al., 2017).
Therefore, more cannabinoids should be tested at this channel in
order to better elucidate structure activity relationships.
TRPM8
The final TRP channel that will be discussed in this review
resides in the melastatin subfamily: TRPM8. TRPM8 is known
for its activation at temperatures below 27◦C and response to
‘‘cooling’’ compounds such as menthol, eucalyptol, and icilin (De
Petrocellis et al., 2007). Similar to TRPV1, TRPM8 is abundantly
expressed in subpopulations of primary afferent neurons (De
Petrocellis et al., 2007). However, in stark contrast to the other
five ionotropic cannabinoid receptors at which cannabinoids
typically act as agonists, TRPM8 is antagonized by cannabinoids.
The juxtaposition between TRPV1 and TRPM8 is interesting
in that TRPV1 undergoes activation followed by desensitization
via dephosphorylation, whereas TRPM8 is regulated by being
inactivated via phosphorylation through protein kinases A and
C in response to cannabinoids (De Petrocellis et al., 2008).
Similar to TRPA1, there are few endocannabinoids that seem
to modulate TRPM8. The endocannabinoids, AEA and NADA
have been identified as the first endogenous antagonists of
TRPM8 and have potencies in the submicromolar region (De
Petrocellis et al., 2007). OtherN-acyl amides have yet to be tested
at TRPM8, which leaves room for more endogenous antagonists
to be identified.
De Petrocellis et al. (2008), who tested numerous
phytocannabinoids on all of the ionotropic cannabinoid
receptors, found that of the 12 cannabinoids tested, nearly
all inhibited the effects of menthol or icilin on TRPM8 with
potencies in the low- to submicromolar range. CBC was
the only phytocannabinoid that was found to be completely
inactive at TRPM8 (De Petrocellis et al., 2008). Interestingly,
CBC was shown to be the most potent cannabinoid at
TRPA1 with a potency of 0.09 ± 0.01 µM (De Petrocellis
et al., 2011b). Table 6 summarizes the potencies of the
cannabinoids tested in comparison to either icilin or
menthol.
Soethoudt et al. (2017) evaluated several synthetic
cannabinoids at TRPM8. Aminoalkylindole derivatives,
TABLE 6 | Functionality of phytogenic, endogenous, and synthetic cannabinoid ligands at TRPM8.
TRPM8
Compound Functionality∗ Potency IC50 (µM) Cell type References
AEA Antagonist vs. icilin 0.15 ± 0.08 TRPM8-HEK-293 De Petrocellis et al. (2007)
Antagonist vs. menthol 3.09 ± 0.61 TRPM8-HEK-293 De Petrocellis et al. (2007)
NADA Antagonist vs. icilin 0.74 ± 0.35 TRPM8-HEK-293 De Petrocellis et al. (2007)
Antagonist vs. menthol 1.98 ± 0.38 TRPM8-HEK-293 De Petrocellis et al. (2007)
THC Antagonist vs. icilin 0.16 ± 0.01 TRPM8-HEK-293 De Petrocellis et al. (2008)
Antagonist vs. menthol 0.15 ± 0.02 TRPM8-HEK-293 De Petrocellis et al. (2008)
THCA Antagonist vs. icilin 0.14 ± 0.02 TRPM8-HEK-293 De Petrocellis et al. (2008)
Antagonist vs. menthol 0.07 ± 0.01 TRPM8-HEK-293 De Petrocellis et al. (2008)
THCV Antagonist vs. icilin 0.87 ± 0.01 TRPM8-HEK-293 De Petrocellis et al. (2011b)
THCVA Antagonist vs. icilin 1.33 ± 0.02 TRPM8-HEK-293 De Petrocellis et al. (2011b)
CBD Antagonist vs. icilin 0.08 ± 0.01 TRPM8-HEK-293 De Petrocellis et al. (2008)
Antagonist vs. menthol 0.14 ± 0.01 TRPM8-HEK-293 De Petrocellis et al. (2008)
CBDA Antagonist vs. icilin 0.9 ± 0.1 TRPM8-HEK-293 De Petrocellis et al. (2008)
Antagonist vs. menthol 1.6 ± 0.4 TRPM8-HEK-293 De Petrocellis et al. (2008)
CBDV Antagonist vs. icilin 0.90 ± 0.01 TRPM8-HEK-293 De Petrocellis et al. (2011b)
CBG Antagonist vs. icilin 0.14 ± 0.01 TRPM8-HEK-293 De Petrocellis et al. (2008)
Antagonist vs. menthol 0.16 ± 0.03 TRPM8-HEK-293 De Petrocellis et al. (2008)
CBGA Antagonist vs. icilin 1.31 ± 0.09 TRPM8-HEK-293 De Petrocellis et al. (2011b)
CBGV Antagonist vs. icilin 1.71 ± 0.04 TRPM8-HEK-293 De Petrocellis et al. (2011b)
CBC Antagonist vs. icilin 40.7 ± 0.6 TRPM8-HEK-293 De Petrocellis et al. (2011b)
CBN Antagonist vs. icilin 0.21 ± 0.05 TRPM8-HEK-293 De Petrocellis et al. (2011b)
SR141716A Antagonist vs. icilin 0.052 ± 0.011 TRPM8-HEK-293 De Petrocellis et al. (2007)
SR144528 Antagonist vs. icilin 0.017 ± 0.005 TRPM8-HEK-293 De Petrocellis et al. (2007)
AM251 Antagonist vs. icilin 18.4 ± 3.5 TRPM8-HEK-293 Soethoudt et al. (2017)
Gp-1a NA >50 TRPM8-HEK-293 Soethoudt et al. (2017)
WIN55,212-2 Antagonist vs. icilin 72.9 ± 4.5 TRPM8-HEK-293 Soethoudt et al. (2017)
(R)-AM1241 NA >50 TRPM8-HEK-293 Soethoudt et al. (2017)
(S)-AM1241 NA >50 TRPM8-HEK-293 Soethoudt et al. (2017)
AM630 Antagonist vs. icilin 4.3 ± 0.3 TRPM8-HEK-293 Soethoudt et al. (2017)
HU308 NA >100 TRPM8-HEK-293 Soethoudt et al. (2017)
HU910 NA >100 TRPM8-HEK-293 Soethoudt et al. (2017)
JWH133 Antagonist vs. icilin 48.4 ± 3.5 TRPM8-HEK-293 Soethoudt et al. (2017)
∗Functionality determined against 0.25 µM icilin or 50 µM menthol. NA, No activity.
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such as AM630 and AM1241, or phytocannabinoid analogs,
such as HU308 or HU910, failed to modulate this channel.
However, certain arylpyrazoles were able to modulate TRPM8.
SR141716A and SR144528 were found to have potencies in the
submicromolar range against icilin. Interestingly, SR141716A,
showed activity in the nanomolar range, therefore potently
modulating three of the six channels discussed in this review.
Since data on cannabinoids at TRPM8 is still sparse, further
studies on its interactions with cannabinoids and the mechanism
of inactivation need to be performed to fully understand the
relevance of this channel.
In general terms, as we can observe from the summarized
data, channel selectivity remains a challenge among cannabinoid
chemotypes. Therefore, further studies should aim at the
identification of novel selective TRP cannabinoids that help
reveal the therapeutic potential and the mechanism of action of
these ligands in the ionotropic receptors.
FINAL REMARKS
It has been widely demonstrated that cannabinoid ligands
exert numerous physiopathological functions by modulating
TRP channels. These cannabinoid-related TRP channels include
members from the vanilloid, ankyrin, andmelastatin subfamilies.
The six channels discussed in this review are also considered
thermo-TRP channels, due to their location in sensory
neurons and their ability to be activated by a wide range
of temperatures. The modulation of these six channels by
temperature and cannabinoids is complex, and the relationship
between the channels and their activation in response to
cannabinoids can be further explored for various therapeutic
uses, including chronic pain and inflammation. Current
knowledge on how and which cannabinoids target TRP channels
is still scarce, but has largely increased in the last decade.
By classifying the cannabinoid structures able to modulate
these receptors, we aim to provide an analysis that helps
identifying key features involved in their activity at each
particular channel.
Of the endocannabinoids tested at the vanilloid-type channels
thus far, all act as agonists with the exception of the
endogenous lipid NVal, which acts as an antagonist of TPRV4.
Endogenous cannabinoids are also able to activate the ankyrin
channel, TRPA1, whereas they exhibit antagonistic effects at
the melastatin receptor, TRPM8. The endocannabinoid, AEA
was found to be the first endogenous agonist at TRPV1 and
has a submicromolar potency. AEA also acts as an agonist
at TRPA1, an antagonist at TRPM8, and indirectly activates
TRPV4 through its cytochrome-450 metabolites (Watanabe
et al., 2003).
Several phytocannabinoids have shown remarkable results at
these channels. The active compounds identified tend to activate
TRPV1–4 and TRPA1, while they antagonize the activation of
icilin or menthol at TRPM8. Among the phytocannabinoids
tested in these six channels, CBD and THCV are the more
promiscuous since they are potent and efficacious modulators of
all the TRP channels discussed here. CBD and CBG are reported
to be the most potent ligands tested at TRPV1.∆9-THC has been
found to show no channel modulation, however, ∆9-THC has
been shown to potently activate TRPV2.
Concerning synthetic cannabinoids, so far only a few,
but from representative cannabinoid scaffolds, have been
tested. Arylpyrazoles such as SR141716A, SR144528, or AM251
(Figure 6) are able to activate TRPA1, while acting as
TRPM8 antagonists. Even though these compounds do not
show activity at the vanilloid channels TRPV2 and TRPV4,
SR141716A and AM251 can weakly modulate TRPV1 and
TRPV3. The aminoalkylindole chemotype has also been explored
at these six channels. For instance, the widely used member
of this class, WIN55,212-2, has been shown to exert some of
its effects through activation of TRPV1 and TRPA1 (Ruparel
et al., 2011). Moreover, phytocannabinoid synthetic derivatives
such as HU308, HU910, and JWH133 have also been tested in
the search of a better understanding of their pharmacological
profile. While HU308 does not display potent modulation of
any of the channels, other analogs in this class do. For example,
JWH133 was shown to modulate TRPV1 and TRPA1 and
antagonize the effects of icilin at TRPM8, while HU910 was
shown to activate TRPV3. HU308 and HU910 share the
dimethoxyphenyl core and the lipophilic side chain, mainly
differing in the position of the aliphatic hydroxyl group. This
feature may determine TRPV3 recognition. On the other hand,
the tricyclic rigidity of JWH133 along with the lack of phenolic
hydroxyl may define the ability of this compound to target
TRPV1 and TRPA1. The structural differences highlighted
here clearly effect the ability of the ligand to modulate their
TRP channels, but how these changes affect the binding
of the ligand in the channel has yet to be determined. A
more inclusive investigation of the binding sites, as well as,
the effects of changing moieties could provide insight on
how to better design cannabinoid ligands for selectivity and
potency.
In summary, we have shown here that a broad range
of cannabinoids (endogenous, phytogenic, and synthetic
cannabinoids) act at one or more of the following ionotropic
channels: TRPV1, TRPV2, TRPV3, TRPV4, TRPA1 and
TRPM8. This information is the first step in understanding the
importance of ionotropic channels to cannabinoid effects, such
as analgesia for chronic pain. However, there is much more
that needs to be discovered. What residues are involved in the
binding of these cannabinoids to the ionotropic cannabinoid
receptors? How do these cannabinoids activate or inactivate the
channels at which they act? What structural modifications will
produce more potent cannabinoids at these channels? Pursuit of
these research directions should lead to a better understanding
of the importance of TRP channels to the physiology of the
endocannabinoid system.
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